Last week I wrote a short update on the company Mesoblast [ASX:MSB]. In that update I noted that the downtrend in the stock had began after ‘after the company received disappointing results from a trial.’
That was a complete mistake on my part, and needs to be corrected. I confused two different companies and wrongly attributed the disappointing trial result to Mesoblast.
The article was removed from our website as soon as I became aware of the error.
I apologise for the mistake.
Editor, Markets and Money